Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Recruiting Phase 1 Interventional Accepts healthy volunteers

Home-based Vision Therapy

NCT06886737
Conditions
Convergence Insufficiency
Interventions
Virtual-reality convergence training game
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Amblyopia
Interventions
Atropine, Plano Lens
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 6 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Fullerton, California • Dallas, Texas
Completed Not applicable Interventional Results available

Study of Binocular Computer Activities for Treatment of Amblyopia

NCT02200211
Conditions
Amblyopia
Interventions
iPad®, Patching 2 hours per day, 7 days per week
Device · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
5 Years to 16 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Rochester, Minnesota • Seattle, Washington
Conditions
Progressive Supranuclear Palsy, Corticobasal Degeneration, Parkinsonism
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
35 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Diabetic Retinopathy
Interventions
PAN-90806 Ophthalmic Solution
Drug
Lead sponsor
PanOptica, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Harlingen, Texas • McAllen, Texas
Recruiting No phase listed Observational Accepts healthy volunteers

Dynamic Light Scattering Ocular Measurement in the Detection of Dementia

NCT06613971
Conditions
Dementia, Dementia Alzheimer Type
Interventions
Not listed
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Coconut Creek, Florida
Conditions
Presbyopia
Interventions
UNR844, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 55 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Laguna Hills, California • Newport Beach, California • Largo, Florida + 8 more
Conditions
Refractive Error, Cataract, Maculopathy
Interventions
Not listed
Lead sponsor
Sinclair Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Elkins Park, Pennsylvania
Conditions
Central Nervous System Lymphoma, Intraocular Lymphoma
Interventions
Intraventricular Rituximab Plus MTX
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York + 1 more
Conditions
Progressive Supranuclear Palsy
Interventions
tideglusib, placebo
Drug
Lead sponsor
Noscira SA
Industry
Eligibility
40 Years to 85 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 3 more
Recruiting Not applicable Interventional

Neurologic Stem Cell Treatment Study

NCT02795052
Conditions
Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions
Intravenous and Intranasal BMSC
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Conditions
Spinal Cord Injury/Disorder
Interventions
Compare two control methods for a wheelchair-mounted robotic manipulator
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers Results available

EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 1

NCT02844543
Conditions
Eye-tracking
Interventions
EYE-SYNC eye-tracking device, SCAT-3, Desktop Eye-Tracker
Device · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 25 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Stanford, California
Recruiting No phase listed Observational Accepts healthy volunteers

Inherited Retinal Degenerative Disease Registry

NCT02435940
Conditions
Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome, Bassen-Kornzweig Syndrome, Batten Disease, Best Disease, Choroidal Dystrophy, Choroideremia, Cone Dystrophy, Cone-Rod Dystrophy, Congenital Stationary Night Blindness, Enhanced S-Cone Syndrome, Fundus Albipunctatus, Goldmann-Favre Syndrome, Gyrate Atrophy, Juvenile Macular Degeneration, Kearns-Sayre Syndrome, Leber Congenital Amaurosis, Refsum Syndrome, Retinitis Pigmentosa, Retinitis Punctata Albescens, Retinoschisis, Rod-Cone Dystrophy, Rod Dystrophy, Rod Monochromacy, Stargardt Disease, Usher Syndrome
Interventions
Not listed
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2037
U.S. locations
1
States / cities
Columbia, Maryland
Conditions
Glaucoma and Ocular Hypertension
Interventions
Brimonidine Tartrate 0.025%, Vehicle
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Winchester, Massachusetts
Conditions
Ocular Inflammation
Interventions
rEV131, Prenisolone sodium phosphate 1.0%, rEV131 vehicle
Drug
Lead sponsor
Evolutec Group
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
North Andover, Massachusetts
Conditions
Amblyopia
Interventions
Eye patch
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 7 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Not applicable Interventional

"Night Vision and Carotenoids"

NCT04741763
Conditions
Macular Degeneration
Interventions
EyePromise Visual Edge
Dietary Supplement
Lead sponsor
Robert Davis
Other
Eligibility
50 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
North Chicago, Illinois • Oak Lawn, Illinois
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Up to 99 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Recruiting No phase listed Observational

Automating Delirium Severity in the ICU

NCT06172491
Conditions
Intensive Care Unit Delirium, Encephalopathy, Delirium
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
400 participants
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Wet Macular Degeneration
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
59
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more
Completed Not applicable Interventional Results available

Luminopia One Amblyopia Vision Improvement Study

NCT03608150
Conditions
Amblyopia
Interventions
Luminopia One, Refractive Correction
Device
Lead sponsor
Luminopia
Industry
Eligibility
4 Years to 7 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Los Angeles, California • Gainesville, Florida • Maitland, Florida + 17 more
Conditions
Amblyopia, Strabismus
Interventions
Binocular Treatment, Sham Binocular Treatment
Procedure
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cataract
Interventions
MELT-300 sublingual tablet, Midalozam sublingual tablet, Placebo sublingual tablet
Drug
Lead sponsor
Melt Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Chico, California • Grand Junction, Colorado • Jacksonville, Florida + 9 more